ReviewAntibiotics (Basel, Switzerland)2022
Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed, 3 syntheses or guidelines pooled it, 236 citations in OpenAlex.
- Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2026Pooled it
- Pooled it
- Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review.Frontiers in microbiology · 2024Pooled it
- ISEmerging microbes & infections · 2026Article
- Review
- Risk factors for infection in NDM-colonized patients and applicability of the Giannella Risk Score.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016-2024).The Journal of antimicrobial chemotherapy · 2026Article
- Reduced Susceptibility to Cefiderocol Among Clinical MCR-1-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Article
- Real-World Use of Cefiderocol for Multidrug-Resistant Gram-Negative Infections in Critically Ill ICU Patients: A Single-Center Case Series.Pathogens (Basel, Switzerland) · 2026Article
- Cefiderocol Susceptibility in Japanese Clinical Enterobacterales Isolates and the Effect of IMP-Type Carbapenemases on Resistance.Antibiotics (Basel, Switzerland) · 2026Article
- Carbapenemases: epidemiology, detection and management in a changing global landscape.JAC-antimicrobial resistance · 2026Review
- Unraveling Cefiderocol Resistance in NDM- and OXA-48-like Co-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections.Antibiotics (Basel, Switzerland) · 2026Review
- Molecular Characterizations of Carbapenem Resistance and Colistin Heteroresistance in Multidrug-Resistant Acinetobacter baumannii.Current microbiology · 2026Article
- Expanding Threat of Carbapenemase-ProducingbioRxiv : the preprint server for biology · 2026Article
- Perspective Approaches to "Trojan Horse" Strategy Development for Combating Bacterial Pathogens.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Molecular Insights into the β‑Lactam α‑Methyl Modulation ofACS omega · 2026Article
- β-Lactamase-Driven Resistance to Cefiderocol in Carbapenem-Resistant Pseudomonas aeruginosa and its Reversal by Avibactam.Current microbiology · 2026Article
- New Insights intoPathogens (Basel, Switzerland) · 2026Review
102 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cefiderocol appears promising, as it can overcome most β-lactam resistance mechanisms (including β-lactamases, porin mutations, and efflux pumps). Resistance is uncommon according to large multinational cohorts, including against isolates resistant to carbapenems, ceftazidime/avibactam, ceftolozane/tazobactam, and colistin. However, alarming proportions of resistance have been reported in some recent cohorts (up to 50%). A systematic review was conducted in PubMed and Scopus from inception to May 2022 to review mechanisms of resistance, prevalence of heteroresistance, and in vivo emergence of resistance to cefiderocol during treatment. A variety of mechanisms, typically acting in concert, have been reported to confer resistance to cefiderocol: β-lactamases (especially NDM, KPC and AmpC variants conferring resistance to ceftazidime/avibactam, OXA-427, and PER- and SHV-type ESBLs), porin mutations, and mutations affecting siderophore receptors, efflux pumps, and target (PBP-3) modifications. Coexpression of multiple β-lactamases, often in combination with permeability defects, appears to be the main mechanism of resistance. Heteroresistance is highly prevalent (especially in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.